Market Access Verona to take COPD hopeful into phase 3 Verona Pharma is to take lung drug RPL554 into late clinical development after a successful phase 2b trial.
News Europe: thumbs up for Roche's Hemlibra, Chiesi rare disease ... Drug has been approved in US since November
News EU regulators back Chiesi drug for rare inherited disease Decision paves way for licence to treat alpha-mannosidosis,
News Verona pushes on with COPD drug after £70m fundraiser UK biotech hopes RPL554 could be a disease modifying drug.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
